3 Einträge gefunden

1. Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer:The Neoadjuvant WSG-TP-II Randomized Clinical Trial

   1. Gluz, Oleg
   2. Nitz, Ulrike A
   3. Christgen, Matthias
   4. Kuemmel, Sherko
   5. Holtschmidt, Johannes
   6. Schumacher, Johannes
   7. Hartkopf, Andreas

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial

   1. Graeser, Monika
   2. Gluz, Oleg
   3. Biehl, Claudia
   4. Ulbrich-Gebauer, Daniel
   5. Christgen, Matthias
   6. Palatty, Jenci
   7. Kuemmel, Sherko

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
3. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

   1. Nitz, Ulrike
   2. Gluz, Oleg
   3. Graeser, Monika
   4. Christgen, Matthias
   5. Kuemmel, Sherko
   6. Grischke, Eva-Maria
   7. Braun, Michael

   2022 - Forschungsinformationssystem des UKE - frei zugänglich